指南与共识脑血管病

脑出血后抗血栓与他汀类药物处方:Get With The Guidelines-Stroke 登记研究

Antithrombotic and Statin Prescription After Intracerebral Hemorrhage in the Get With The Guidelines-Stroke Registry.
指南 / 共识 · Stroke · 2023-11-09

该横断面研究纳入 Get With The Guidelines-Stroke 登记中 2011 至 2021 年的脑出血患者,分析出院时抗血栓和他汀类药物处方模式及相关因素。结果显示出院时抗血小板药、他汀和抗凝治疗处方比例分别为 10.4%、35.1% 和 5.4%。作者认为脑出血后抗血小板和降脂治疗的净获益有待试验验证。

要点

  • 脑出血患者出院时抗血小板药处方比例为 10.4%,他汀为 35.1%,抗凝为 5.4%。
  • 有脑出血前用药史者抗血小板治疗比例为 16.6%,有缺血性血管病者为 15.6%。
  • 作者认为需开展试验验证脑出血后抗血小板和降脂治疗的净获益。

核心结论

  • 脑出血患者出院时接受抗血栓或他汀类药物治疗的比例较低。
  • 鉴于脑出血与未来主要心血管事件之间新出现的关联,有必要开展试验验证脑出血后抗血小板和降脂治疗的净获益。

研究设计与样本

  • Get With The Guidelines-Stroke 登记中 2011 至 2021 年脑出血患者的横断面研究。
  • 排除转至其他医院、住院期间死亡及出院用药信息缺失的患者。
  • 最终队列中,抗血小板分析纳入 486 586 例,他汀分析纳入 493 491 例,抗凝分析纳入 486 585 例。

主要发现

  • 出院时抗血小板药处方为 50 416/486 586 例(10.4%),他汀为 173 322/493 491 例(35.1%),抗凝为 27 085/486 585 例(5.4%)。
  • 有脑出血前抗血小板用药史者抗血小板治疗比例为 16.6%,有既往缺血性血管病者为 15.6%。
  • 有既往降脂治疗者他汀处方比例为 41.1%,有缺血性血管病者为 43.7%。
  • 抗凝治疗在 11.1% 的患者中重新启动。
  • 多因素 logistic 回归分析显示,与抗血栓或他汀治疗使用率较高相关的因素包括较年轻年龄、男性、脑出血前用药、既往缺血性血管病、心房颤动、较低入院美国国立卫生研究院卒中量表评分、较长住院时间及良好出院结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survivors of intracerebral hemorrhage (ICH) face an increased risk of ischemic cardiovascular events. Current ICH guidelines do not provide definitive recommendations regarding the use of antithrombotic and statin therapies. We, therefore, sought to study practice patterns and factors associated with the use of such medications after ICH. METHODS: This was a cross-sectional study of patients with ICH in the Get With The Guidelines-Stroke registry, between 2011 and 2021. Patients transferred to another hospital, those who died during hospitalization, and those with missing information on discharge medications were excluded. The study exposure was the proportion of patients who were prescribed antithrombotic or statin medications. We first ascertained the proportion of patients prescribed antithrombotic and lipid-lowering medications at discharge overall and across strata defined by pre-ICH use and history of previous ischemic vascular disease or atrial fibrillation. We then studied factors associated with the discharge prescription of these medications after ICH, using multiple logistic regressions. RESULTS: In the final cohort, 50 416 (10.4%) of 486 586 patients with ICH were prescribed antiplatelet medications, 173 322 (35.1%) of 493 491 patients with ICH were prescribed statins, and 27 085 (5.4%) of 486 585 patients with ICH were prescribed anticoagulation therapy at discharge. The proportion of patients with antiplatelet therapy was 16.6% with pre-ICH use and 15.6% in those with previous ischemic vascular disease. Statins were prescribed to 41.1% and 43.7% of patients on previous lipid-lowering therapy and ischemic vascular disease, respectively. Anticoagulation therapy was restarted in 11.1% of patients. In logistic regression analysis, factors associated with higher use of antithrombotic or statin therapies after ICH were younger age, male sex, pre-ICH medication use, previous ischemic vascular disease, atrial fibrillation, lower admission National Institutes of Health Stroke Scale, longer length of stay, and favorable discharge outcome. CONCLUSIONS: Few patients with ICH are prescribed antithrombotic or statin therapies at hospital discharge. Given the emerging association between ICH and future major cardiovascular events, trials examining the net benefit of antiplatelet and lipid-lowering therapy after ICH are warranted.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Murthy SB, Zhang C, Shah S, et al. Antithrombotic and Statin Prescription After Intracerebral Hemorrhage in the Get With The Guidelines-Stroke Registry. Stroke. 2023. PMID: 37942641. doi:10.1161/STROKEAHA.123.043194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。